Antibody-based therapy in colorectal cancer

Immunotherapy

Volumn 5, Issue 5, 2013, Pages 533-545

  Noguchi, Takuro ^a   Ritter, Gerd ^a   Nishikawa, Hiroyoshi ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

antibody; antibody dependent cellular cytotoxicity; antibody facilitated T cell immunity; colorectal cancer; complement dependent cellular cytotoxicity; Fc receptor; immune checkpoint

Indexed keywords

ADECATUMUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CDX 1127; CEP 37250; CETUXIMAB; CIXUTUMUMAB; CONATUMUMAB; DEMCIZUMAB; DROZITUMAB; EDRECOLOMAB; ENSITUXIMAB; ETARACIZUMAB; FIGITUMUMAB; GANITUMAB; GS 6624; HA 33; HU3S193; ICRUCUMAB; IMGATUZUMAB; IMMUNOGLOBULIN; ING 1; KRN 330; L 19; MDX 1105; MEHD 7945A; MGA 271; NECITUMUMAB; NIMOTUZUMAB; NIVOLUMAB; PANITUMUMAB; PIDILIZUMAB; RAMUCIRUMAB; SILTUXIMAB; TRASTUZUMAB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALUTUMUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BINDING COMPETITION; BONE MARROW CELL; BREAST CANCER; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPETITIVE INHIBITION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEX FORMATION; CONGESTIVE CARDIOMYOPATHY; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG EFFICACY; GENETIC POLYMORPHISM; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TUMOR MICROENVIRONMENT; UPREGULATION; WILD TYPE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; TREATMENT OUTCOME;

EID: 84877275493     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.35     Document Type: Review

References (107)

1. Van Loon K, Venook AP. Adjuvant treatment of colon cancer: what is next? Curr. Opin. Oncol. 23(4), 403-409 (2011).
2. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin. Ther. 32(3), 437-453 (2010).
3. Welt S, Ritter G. Antibodies in the therapy of colon cancer. Semin. Oncol. 26(6), 683-690 (1999).
4. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
5. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
6. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
7. Argiles G, Dienstmann R, Elez E, Tabernero J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol. 8(4), 373-389 (2012).
8. Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of FcgRIIa-FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27(7), 1122-1129 (2009).
9. Zhang W, Gordon M, Schultheis AM et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25(24), 3712-3718 (2007).
10. Mulder K, Scarfe A, Chua N, Spratlin J. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opin. Biol. Ther. 11(3), 405-413 (2011).
11. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
12. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol. 25(30), 4779-4786 (2007).
13. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
14. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2049 (2008).
15. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin aVb3 in the disruption of the tumor vasculature induced by TNF and IFN-g. Nat. Med. 4(4), 408-414 (1998).
16. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7(2), 95-106 (2007).
17. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
18. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
19. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
20. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
21. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007).
22. Weiner GJ. Rituximab: mechanism of action. Semin. Hematol. 47(2), 115-123 (2010).
23. Di Gaetano N, Cittera E, Nota R et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171(3), 1581-1587 (2003).
24. Racila E, Link BK, Weng WK et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 14(20), 6697-6703 (2008).
25. Nimmerjahn F, Ravetch JV. Fcg receptors as regulators of immune responses. Nat. Rev. Immunol. 8(1), 34-47 (2008).
26. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6(4), 443-446 (2000).
27. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753), 1510-1512 (2005).
28. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcg receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203(3), 743-753 (2006).
29. Bruhns P, Iannascoli B, England P et al. Specificity and affinity of human Fcg receptors and their polymorphic variants for human IgG subclasses. Blood 113(16), 3716-3725 (2009).
30. Weng W, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21), 3940-3947 (2003).
31. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11), 1789-1796 (2008).
32. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7(9), 1401-1413 (2007).
33. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787), 670-673 (2006).
34. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110(1), 71-79 (2002).
35. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J. Exp. Med. 195(12), 1653-1659 (2002).
36. Wolpoe ME, Lutz ER, Ercolini AM et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171(4), 2161-2169 (2003).
37. Kim PS, Armstrong TD, Song H et al. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J. Clin. Invest. 118(5), 1700-1711 (2008).
38. Saenger YM, Li Y, Chiou KC et al. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res. 68(23), 9884-9891 (2008).
39. Balzar M, Winter MJ, De Boer CJ, Litvinov S. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. (Berl.) 77(10), 699-712 (1999).
40. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. Natl Acad. Sci. USA 76(3), 1438-1442 (1979).
41. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 125(2), 437-446 (1994).
42. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23(34), 5748-5758 (2004).
43. Maetzel D, Denzel S, Mack B et al. Nuclear signaling by tumour-associated antigen EpCAM. Nat. Cell Biol. 11(2), 162-171 (2009).
44. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 40(3), 717-721 (1980).
45. Riethmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343(8907), 1177-1183 (1994).
46. Hartung G, Hofheinz RD, Dencausse Y et al. Adjuvant therapy with edrecolomab versus observation in Stage II colon cancer: a multicenter randomized Phase III study. Onkologie 28(6-7), 347-350 (2005).
47. Niedzwiecki D, Bertagnolli MM, Warren RS et al. Documenting the natural history of patients with resected Stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J. Clin. Oncol. 29(23), 3146-3152 (2011).
48. Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of Stage III colon cancer: a randomised study. Lancet 360(9334), 671-677 (2002).
49. Khazaeli MB, Saleh MN, Wheeler RH et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J. Natl Cancer Inst. 80(12), 937-942 (1988).
50. Munz M, Murr A, Kvesic M et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int. 10, 44 (2010).
51. Marschner N, Ruttinger D, Zugmaier G et al. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol. Int. 85(4), 386-395 (2010).
52. Goel S, Bauer RJ, Desai K et al. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Ann. Oncol. 18(10), 1704-1707 (2007).
53. Kim YS, Yuan M, Itzkowitz SH et al. Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res. 46(11), 5985-5992 (1986).
54. Liu J, Lin B, Hao Y et al. Lewis Y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J. Exp. Clin. Cancer Res. 28, 154 (2009).
55. Li F, Lin B, Hao Y et al. Lewis Y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors. Int. J. Mol. Sci. 11(10), 3748-3759 (2010).
56. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 50(7), 2183-2190 (1990).
57. Trail PA, Willner D, Lasch SJ et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261(5118), 212-215 (1993).
58. Tolcher AW, Sugarman S, Gelmon KA et al. Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17(2), 478-484 (1999).
59. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional Phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 6(2), 78-81 (2000).
60. Scott AM, Geleick D, Rubira M et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 60(12), 3254-3261 (2000).
61. Scott AM, Tebbutt N, Lee FT et al. A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin. Cancer Res. 13(11), 3286-3292 (2007).
62. Smaletz O, Diz MDP, Carmo CC et al. Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC). J. Clin. Oncol. 29(Suppl.), Abstract 5078 (2011).
63. Kircheis R, Halanek N, Koller I et al. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. MAbs 4(4), 532-541 (2012).
64. Ritter G, Cohen LS, Nice E et al. Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem. Biophys. Res. Commun. 236(3), 682-686 (1997).
65. Heath JK, White SJ, Johnstone CN et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc. Natl Acad. Sci. USA 94(2), 469-474 (1997).
66. Garinchesa P, Sakamoto J, Welt S et al. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int. J. Oncol. 9(3), 465-471 (1996).
67. Welt S, Divgi CR, Real FX et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a Phase I study of monoclonal antibody A33. J. Clin. Oncol. 8(11), 1894-1906 (1990).
68. Welt S, Scott AM, Divgi CR et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol. 14(6), 1787-1797 (1996).
69. Welt S, Ritter G, Williams C Jr et al. Phase I study of anticolon cancer humanized antibody A33. Clin. Cancer Res. 9(4), 1338-1346 (2003).
70. Scott AM, Lee FT, Jones R et al. A Phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin. Cancer Res. 11(13), 4810-4817 (2005).
71. Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA et al. (124)I-huA33 antibody PET of colorectal cancer. J. Nucl. Med. 52(8), 1173-1180 (2011).
72. Bendell JC, Marshall J, Berlin J et al. KRN330, a fully human antibody against A33, in combination with irinotecan for patients with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 29(Suppl. 4), Abstract 534 (2011).
73. Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95, 1-30 (2006).
74. Nagata Y, Ono S, Matsuo M et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl Acad. Sci. USA 99(16), 10629-10634 (2002).
75. Noguchi T, Kato T, Wang L et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res. 72(7), 1672-1682 (2012).
76. Muraoka D, Kato T, Wang L et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J. Immunol. 185(6), 3768-3776 (2010).
77. Gupta A, Nuber N, Esslinger C et al. A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immun. 13, 3 (2013).
78. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330-337 (2012).
79. Matsushita H, Vesely MD, Koboldt DC et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385), 400-404 (2012).
80. Dupage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482(7385), 405-409 (2012).
81. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
82. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229(1), 12-26 (2009).
83. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7(6), 885-895 (1997).
84. Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899), 271-275 (2008).
85. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
86. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190(3), 355-366 (1999).
87. Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28(21), 3485-3490 (2010).
88. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107(17), 7875-7880 (2010).
89. Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2), 141-151 (1999).
90. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502), 319-322 (2001).
91. Okazaki T, Tanaka Y, Nishio R et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9(12), 1477-1483 (2003).
92. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8(6), 467-477 (2008).
93. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
94. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17(2), 133-144 (2005).
95. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
96. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
97. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
98. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
99. Mitsui J, Nishikawa H, Muraoka D et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 16(10), 2781-2791 (2010).
100. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
101. White AL, Chan HT, Roghanian A et al. Interaction with FcgRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187(4), 1754-1763 (2011).
102. Li F, Ravetch JV. Inhibitory Fcg receptor engagement drives adjuvant and antitumor activities of agonistic CD40 antibodies. Science 333(6045), 1030-1034 (2011).
103. Wilson NS, Yang B, Yang A et al. An Fcg receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19(1), 101-113 (2011).
104. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
105. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654-2666 (2005).
106. Study of adecatumumab relative to FOLFOX after R0 resection of colorectal liver metastases (MT201-204). http://clinicaltrials.gov/show/NCT00866944
107. ClinicalTrials.gov. http://clinicaltrials.gov